Clinical trial
Reduction or Discontinuation of CNI's With Conversion to Everolimus-Based…
NCT00443508 · Rabin Medical Center, Other · Unknown status
Key facts
| NCT number | NCT00443508 |
|---|---|
| Title | Reduction or Discontinuation of CNI's With Conversion to Everolimus-Based Immunosuppresion |
| Official title | Reduction or Discontinuation of Calcineurine Inhibitors With Conversion to Everolimus-Based Immunosuppresion to Alleviate Chronic Allograft Nephropathy (CAN) in Kidney Transplant Recipients: A Prospective Randomized Study |
| Lead sponsor | Rabin Medical Center, Other |
| Collaborators | Novartis Industry |
| Status | Unknown status |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Kidney Diseases |
| Intervention type | Drug |
| Interventions | adding Certican to therapy, reducing Tacrolimus |
| Enrollment | 60 |
| Start date | Feb 1, 2007 |
| Completion | Feb 1, 2010 |
| First posted | Mar 6, 2007 |
| Last update posted | Mar 6, 2007 |
| Countries | Israel |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: